Comparative Pharmacology
Head-to-head clinical analysis: ATHROMBIN versus ATHROMBIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHROMBIN versus ATHROMBIN K.
ATHROMBIN vs ATHROMBIN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin and factor Xa, thereby preventing fibrin clot formation.
Antithrombin III (AT III) activation and factor Xa inhibition via heparin cofactor II binding.
Adult: 15 mg subcutaneously twice daily. For initial treatment of venous thromboembolism, 30 mg subcutaneously every 12 hours for 5-7 days.
2.5-5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged to 15-20 hours in moderate renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 4-6 hours in patients with normal renal function; prolonged in renal impairment.
Renal: 40-60% as unchanged drug; fecal/biliary: 20-30% as metabolites; terminal phase extended in renal impairment.
Primarily renal (urinary) as unchanged drug and metabolites, accounting for ~60-70% of elimination; biliary/fecal excretion accounts for ~20-30%.
Category C
Category C
Hemostatic Agent
Hemostatic Agent